So what: Advertising regulations apply regardless of the format. Slides at a scientific symposium, verbal explanations by a medical representative, or digital content all carry the same standard. Labelling something "information provision" does not create an exemption.

So why: This prohibition closes the loophole by which companies might otherwise avoid advertising rules by relabelling promotional communications as "educational." Activities covered by these Guidelines are subject to the same standard as formal advertising under the PMD Act.

So what: "Recommendation" is not limited to explicit instructions. A statement that "efficacy has been shown in this patient population" or "research into off-label applications is advancing" can constitute a recommendation depending on context.

So why: Unapproved use means use that has not been evaluated for safety and efficacy under Japan's regulatory process. Allowing companies to actively circulate unapproved-use information would expand such use without the benefit of that evaluation, exposing patients to unquantified risk.

So what: A factually accurate statement about prescription volume — "this medicine is the most frequently prescribed in its class" — does not become permissible inducement simply because it is true. The evidence required is clinical: efficacy and safety data, not utilisation statistics.

So why: Prescribing decisions must be grounded in scientific evidence. Social proof and appeal to authority exploit cognitive shortcuts that bypass evidence-based reasoning, undermining the foundation of clinical decision-making that regulators rely on to protect patients.

So what: A statement that "Drug X has fewer adverse events than Drug Y" may be permissible if supported by a direct comparison trial — but disproportionately emphasising "Drug Y causes serious adverse events" crosses into disparagement even when the underlying fact is accurate.

So why: Competitive attacks exploit emotional reactions and divert attention from scientific comparison. The forum for prescription drug information should be one of clinical reasoning, not adversarial marketing.

So what: The threshold is contextual: how far does the presentation deviate from standard medical risk communication for the condition? Translating statistical risk into emotionally charged language, or presenting only worst-case scenarios, are typical examples of "excessive" emphasis.

So why: Fear-based information shifts the prescribing motive from rational clinical judgment to emotional reaction. Accurate risk communication has a legitimate place; engineering anxiety to drive prescriptions does not.

So what: "Please consult your doctor about this condition" is generally acceptable. "Drug treatment is necessary" or "early pharmacotherapy is recommended" in awareness communications that implicitly single out a specific medicine veers into prohibited territory.

So why: Disease awareness is legitimately aimed at encouraging appropriate medical consultation and informed health decisions. When it serves instead as a vehicle for expanding drug prescriptions, patients lose access to balanced information about all their options. Maintaining the boundary between awareness and promotion protects patient autonomy.

So what: "It is not explicitly listed" is not a defence. If a new communication method could reasonably lead to improper use, it falls under this clause regardless of whether a specific rule addresses it.

So why: Any enumerated list leaves gaps; the catch-all clause prevents companies from exploiting those gaps through technical innovation or novel framing. It also signals that the purpose of the Guidelines — protecting appropriate use — takes precedence over literal compliance with a fixed list.